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INTRODUCTION
Antigens are presented to CD4 + T cells by specialized antigenpresenting cells (APCs), such as dendritic cells, through major histocompatibility complex (MHC) class II molecules. CD4 + T cells recognize the antigens through their T cell receptors (TCRs) (1) (2) (3) (4) . These cells also receive signals through the co-receptor CD4, costimulatory receptors (such as CD28), and other stimulatory and inhibitory accessory receptors (5) (6) (7) . These receptors sense the cytokines and other molecules in the microenvironment surrounding the cells and on the surface of the APCs. T cells integrate these signals, which results in their activation and differentiation into specialized effector cells (7) (8) (9) (10) (11) . CD4 + T cells coordinate the adaptive immune response through cell-to-cell contacts and the secretion of cytokines that influence the activity of other cell types. TCR signaling has been a major research topic during the last decade, in particular with a view to identifying new targets to inhibit, enhance, or alter the outcome of T cell activation. However, an updated comprehensive version of this crucial pathway is missing. In recent years, new high-throughput technologies have enabled substantial advances in the field, revealing an unprecedented level of complexity of TCR signaling (12) (13) (14) (15) (16) (17) (18) .
TCR-mediated signaling can be divided into four main modules: (i) early signaling, which is characterized by the recruitment and phosphorylation of LCK (lymphocyte cell-specific protein tyrosine kinase); (ii) the formation of signalosome complexes containing LAT (linker for activation of T cells), CD6 (T cell differentiation antigen), or both; (iii) the activation of important mediators such as protein kinase C  (PKC); and (iv) downstream signaling through mitogen-activated protein kinases (MAPKs), inhibitor of nuclear factor B (NF-B) kinase (IKK) kinases, and Ca
2+
-mediated signaling (19) (20) (21) (22) . TCR signaling results in the activation of inducible transcription factors, which, in turn, promote changes in gene expression. The main transcription factors that mediate TCR-inducible gene expression are NFAT (nuclear factor of activated T cells), NF-B, AP-1 (activator protein 1), and CREB (adenosine 3′,5′-monophosphate response element-binding protein) (20, (23) (24) (25) (26) (27) (28) . A proper balance between the activation of these transcription factors leads to robust T cell activation and differentiation, whereas imbalances may induce an impaired immune response, which can result in anergy or apoptosis (4, (29) (30) (31) (32) . For example, NF-B and NFAT are both members of the Rel family of transcription factors and may compete for binding motifs on DNA targets. A balance between NFAT and NF-B affects the phenotype of the cells. When NF-B activity is greater than that of NFAT, the cell exhibits a proinflammatory response, whereas the absence of NF-B activity leads to an anti-inflammatory response (33) (34) (35) (36) . Other transcription factors that respond to TCR activation include -catenin (37, 38) and serum response factor (SRF) (39) .
T cell activation takes place in the lymph nodes where, in addition to the signals provided by APCs, pieces of antigens and molecules secreted by other cells circulate. Among these, the flagellin monomer is directly recognized by CD4 + T cells through the cell surface receptor Toll-like receptor 5 (TLR5) (40, 41) . TLRs are important modulators of the cellular response, and triggering their activation through appropriate vaccine adjuvants is a promising therapeutic approach. TLR expression, signaling, and function have been characterized in cells of the innate immune system (42) (43) (44) (45) . TLR signaling is initiated by ligand binding, dimerization of receptors, and recruitment of the adaptor protein MyD88 (myeloid differentiation primary response protein) or TRIF [Toll-interleukin-1 (IL-1) receptor domain-containing adapter inducing interferon- (IFN-)]. With the exception of TLR3, all TLRs recruit MyD88, whereas TLR3, TLR4, and TLR5 recruit TRIF. These adaptors induce the sequential recruitment and activation of a series of kinases of the IRAK (IL-1 receptor-associated kinase) family, leading to the activation of IKKs and MAPKs (45) (46) (47) (48) . The activation of TLRs can also stimulate the phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) pathway, leading to the activation of the transcription factors AP-1 and CREB (49) (50) (51) . Together, downstream of TLR signaling, NF-B, AP-1, and CREB are activated. When TLRs recruit TRIF, members of the interferon response factor (IRF) family of transcriptional regulators are also activated (52, 53) .
Flagellin, a component of the flagella of many bacteria and a ligand of TLR5, has been proposed as a vaccine adjuvant for its ability to induce a proinflammatory response in several cell types (54) (55) (56) (57) . Although classically studied for its function in cells of the innate immune system, TLR5 is one of the main TLRs expressed in T cells. In CD4 + T cells, TLR5 function is not well characterized, but it was reported that TLR5 costimulatory signals can induce proliferation and expression of cytokines, such as IFN- (58). Moreover, CD4
+ and CD8 + T cells respond to TLR5 costimulatory signals (59, 60) .
To better understand the role of TCR signaling network in the activation of key transcription factors, focusing in particular on the interplay between TCR-and TLR5-mediated signaling, we have used two complementary computational approaches to generate (i) detailed molecular maps of the TCR and TLR5 pathways and (ii) predictive qualitative models of the dynamical behavior of these pathways, taking into account documented cases of cross-talk. To build and refine these models, we took advantage of the RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) data generated by the BLUEPRINT consortium (www. blueprint-epigenome.eu/). Furthermore, we evaluated the activation of c-Jun, p65, and CREB upon engagement of the TCR in the absence or presence of the TLR5 ligand flagellin. Model predictions were systematically compared with experimental data to refine and validate our models. Our combined experimental and modeling analyses indicate that TLR5 is a costimulatory receptor of the TCR, with an effect on cell activation comparable to that of CD28.
RESULTS

Generation of a molecular map and a logical model for the TCR pathway
We collected information from public databases, in particular Reactome and Kyoto Encyclopedia of Genes and Genomes (KEGG), and curated the literature to construct a molecular map describing the TCR signaling network ( fig. S1 and data file S1). Using the software GINsim (http://ginsim.org), we then built a detailed logical model describing TCR-mediated signaling in CD4 + T cells, taking as starting point the model published by Saez-Rodriguez et al. (61) and substantially updating it with data previously integrated in the molecular map. We mainly used data from primary human and mouse CD4 + T cells, which were completed with information from human CD8 + T cells, as well as from Jurkat cells and other cell lines, assuming that key signaling events are conserved between T cells and furthermore between mice and humans. The model, nevertheless, keeps track of the origin of the information (cell lines, species, and bibliographical entries) in the annotations associated with each component. To ensure that all model components were effectively expressed in CD4 + T cells, we checked their expression using public RNA-seq and ChIP-seq data (table S1 and Materials and Methods). The resulting TCR-mediated signaling model encompasses 110 nodes (Fig. 1 and data file S2 ). In particular, TCR and CD28 correspond to the canonical receptors that initiate the activation of CD4 + T cells (represented by green nodes in Fig. 1 ). Other nodes, such as CD4, CD45, CD6, RCAN1, and Akap5, correspond to model inputs for which we considered a default value of 1 or 0 (see table S5 ). In vivo, TCR signals are provided by an antigenic peptide presented by APCs in association with MHCII molecules. CD4 recognizes the MHCII molecule itself, and CD28 recognizes the costimulatory molecules (CD80 and CD86) expressed in activated APCs.
We included the key transcription factors NF-B (NFkB in the model and in Fig. 1 ), AP-1 (AP1), NFAT (NFAT), CREB (CREB1), SRF (SRF), and -catenin (CTNNB1) (Fig. 1, yellow nodes) . A combination of these transcription factors regulates most of the effector genes expressed during CD4 + T cell activation. To facilitate interpretation, we further explicitly included phenotypic nodes (Fig. 1 , output nodes in gray) representing functional responses: proinflammatory cytokines (PICytokines), anti-inflammatory cytokines (AICytokines), cell cycle progression (CellCycleProg), survival (Survival), cytoskeleton rearrangement (ActinRem), and anergy (Anergy). The model was then completed by assigning a logical rule to each node (table S2). These logical rules describe how the activation status of each node is determined by the amount of its regulators (see Materials and Methods). We computed the stable states of the TCR model and compared them with the experimental behavior of the TCR pathway as reported in the literature. Observed discrepancies led us to refine the model rules (see Supplementary Text) until a reasonable qualitative match was obtained (see Fig. 2 ). For example, stimulation of the TCR alone induces NFAT activation and a state of anergy, whereas stimulation of both the TCR and CD28 induces the activation of NFAT, NF-B, AP-1, and CREB, promoting cytoskeleton rearrangement, survival, cell cycle progression, and the expression of pro-and anti-inflammatory cytokines. Next, we assessed the behavior of our model in the context of either knockout (KO) or inhibition of PI3K (PI3K) or PKC (PKCth). The model correctly reproduces several scenarios. First, when only TCR signals are present (without costimulation), a state of anergy is reached, which is characterized by the activation of NFAT and the lack of AP-1 and NF-B activation. Second, when both the TCR and CD28 are stimulated, all six transcription factors are activated. Third, when PI3K activity is impaired, the activation of AP-1 and NF-B is compromised (which would lead to anergy). This occurs because PI3K contributes to the activation of NF-B (62) and AP-1 (63) . Fourth, our model accounts for the fact that NF-B cannot be activated by TCR signals (either alone or in combination with CD28 signals) when PKC is impaired, because of the lack of proper activation of IKK (23, 64) . In this case, our model predicts that the production of proinflammatory cytokines, cell cycle, and survival, for which NF-B is essential, would be affected when this transcription factor is not activated, but that the production of anti-inflammatory cytokine would be unaffected.
Generation of a molecular map and a logical model for TLR5 pathway
Similarly, to study the role of TLR5 signaling in naïve CD4 + T cells, we generated a detailed molecular map ( fig. S2 and data file S3) and a logical model ( Fig. 3 and data file S4) for this pathway. Our TLR5 logical model encompasses 42 nodes, including one input component, TLR5, which is activated by flagellin. The model further includes the transcription factors NF-B (NFkB), AP-1 (AP1), and CREB White cells (value 0) denote negligible activation of the corresponding components (columns), whereas blue cells (value 1) denote substantial activation. Inputs are highlighted in green, phenotypical nodes are in gray, and the transcription factors induced during T cell activation are in yellow.
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(CREB1), together with three phenotypic (output) nodes representing proinflammatory cytokines (PICytokines), anti-inflammatory cytokines (AICytokines), and cell survival (Survival). As for the TCR model, we used transcriptomic and epigenetic data from the BLUE-PRINT consortium (table S1) to verify the expression of the signaling molecules. We kept only those components associated with active enhancers (H3K4me1 and H3K27ac marks) and/or active promoters (H3K4me3 and H3K27ac marks), together with statistically significant gene expression as reported in the RNA-seq data ( fig. S3 ). Last, a logical rule was assigned to each node of the TLR5 regulatory graph (table S3) as for the TCR model (see Materials and Methods). To challenge our TLR5 model (Fig. 3) , we compared model simulations with published experimental data for the wildtype situation, as well as for TAK1 (transforming growth factor -activated kinase) and PI3K KOs (Fig. 4) . The simulation of the TAK1 KO resulted in the loss of activation of NF-B, AP-1, and CREB, as observed previously (49, (65) (66) (67) (68) . Similarly, simulation of the PI3K KO resulted in the impairment of NF-B, AP-1, and CREB activation, consistent with previous studies (62, 63, 69, 70) .
Cooperation between TCR and TLR5 signals for T cell activation
To analyze the interactions between TCR and TLR5 pathways and their role in T cell activation, we merged our TCR and TLR5 models Fig. 5 . The TCR + TLR5 merged model. The merged model encompasses 128 nodes, including 3 externally controlled inputs (TLR5, TCR, and CD28) and 6 phenotypic nodes (bottom). The pink nodes belong to the original TCR model, the blue nodes belong exclusively to the original TLR5 model, and the yellow nodes are shared between the two models. Green arrows represent activation events, whereas red blunt-end arcs denote inhibition events.
using the GINsim software (Fig. 5, table S4 , and data file S5). Our merged model encompasses 128 nodes, including 3 externally controlled inputs (TCR, CD28, and TLR5) and 6 phenotypic (output) nodes. Although both receptors coincide in the activation of common transcription factors, the signaling pathways leading to transcription factor activation are mostly independent. Next, we computed the stable states of the resulting model for wild-type and mutant backgrounds and adjusted the rules of the components lying at the intersection between the two original models to consider all regulatory inputs and to be consistent with the experimental data ( Fig. 6; fig. S4) . The reduced merged model encompasses 59 components. This model was then used to simulate T cell activation by different combinations of signals. According to these simulations, TLR5 signals induce the activation of the PI3K, NF-B, and MAPK pathways (Fig. 4) . We hypothesized that this activation process could synergize with TCR signals to induce a productive activation of naïve CD4 + T cells.
Experimental validation of the merged TCR and TLR5 model
To challenge our merged TCR + TLR5 model, we studied the response of naïve CD4 + T cells to stimulation of the TCR alone, of TLR5 alone, of the TCR together with TLR5, and of the TCR together with CD28, in strong and weak activation conditions, and assessed the phosphorylation of p65, c-Jun, and CREB1. As strong stimulus, we used a high concentration (1 g/ml) of each anti-CD3 and anti-CD28 antibody cross-linked with a goat anti-mouse antibody, as reported by others (71) (72) (73) (74) (75) . We further used a lower concentration (0.1 g/ml) of each antibody to achieve a weak or suboptimal stimulation (74) (75) (76) (77) . Although all the evaluated molecules showed a basal level of phosphorylation, statistically significantly greater phosphorylation was achieved when the cells were exposed to strong stimuli of TCR alone (for CREB activation) or of TCR and costimulatory signals (for p65 and c-Jun) (Fig. 7) . Weak signals by the TCR or costimulatory molecules in different combinations resulted in wide variations in the extent of p65 and c-Jun activation, suggesting that signaling strength must exceed a threshold to result in robust activation of the cell population, which only under strong TCR stimulation and costimulation was reproducible in every biological sample. Furthermore, the combination of TCR and TLR5 stimulation gave rise to a similar response to that induced by costimulation of the TCR and CD28. Together, our experimental results thus suggest the potential of flagellin to provide costimulatory signals directly to T cells, as predicted by our logical simulations.
DISCUSSION
We generated detailed molecular maps and logical models for TCR and TLR5 signaling pathways, which were adapted to human naïve CD4 + T cells, taking into account the expression and epigenetic status of the main genes involved. These models were fine-tuned until reaching a behavior in agreement with experimental data, including four documented perturbations. These models were then merged to generate a combined TCR + TLR5 model, which was used to predict the activation of key transcription factors upon induction of each or both pathways. Simulation results were compared with experimental results regarding the activation of c-Jun (AP-1), CREB, and p65 (NF-B). Our simulations and experimental results point to a potential role of TLR5 costimulatory signals in the activation and differentiation of CD4 + T cells through the induction of AP-1, CREB, and NF-B activation, which can, in turn, induce (directly or through other transcription factors) the expression of several genes encoding cytokines, receptors, and signaling molecules.
According to our modeling and experimental results, the TLR5 pathway cooperates with TCR signals to induce NF-B and AP-1 activation. This could explain the role of TLR5 in the proliferation of CD4 + T cells, as well as the production of the cytokines IFN- and IL-8 (58). However, although both the TCR and TLR5 resulted in the activation of common transcription factors, the signaling pathways leading to transcription factor activation were mostly independent. This suggests that the TLR5 pathway could act as a rescue pathway to enable CD4 + T cell activation in immunodeficient conditions, for example, when important signaling molecules of the TCR pathway are inactive or inadequately functioning. In this respect, we previously recently reported (78) that TLR5 signals play a proinflammatory role in neonatal and adult CD4 + T cells, leading to the production of IFN-. Thus, TLR5 contributes to overcome the higher activation threshold of neonatal CD4 + T cells, which are characterized by defective TCR/CD28-mediated AP-1 activation (79). Consistent with this finding, flagellin is a good adjuvant, inducing protection in a neonatal mouse vaccination model of rotavirus infection (78) .
In summary, combining computational modeling and experimental validations, our combined experimental and modeling analysis demonstrates that TLR5 is a costimulatory receptor for CD4 + T cells and that it uses a different pathway than that used by CD28 to induce the activation of the transcription factors NF-B and AP-1. This function of TLR5 is independent of its role in innate immunity, because our experiments were performed with isolated, naïve CD4 + T cells. However, both functions of TLR5 might be important for a full immune response in vivo.
MATERIALS AND METHODS
Generation of molecular maps
We generated detailed molecular maps for the TCR and TLR5 signaling pathways using the software CellDesigner (www.celldesigner.org/).
To do this, we relied on data gathered from the literature and from databases such as KEGG (www.genome.jp/kegg/), Reactome (www. reactome.org/), and DC-ATLAS (http://compbiotoolbox.fmach.it/ DCATLAS.php). In CellDesigner, there are three possible types of Components, which are Species, Reactions, and Compartments. A Species represents a protein, a complex, or some other molecule in a biochemical or regulatory network. On the other hand, a Reaction can be a chemical reaction, a physical interaction between Species, or a regulatory relation between genes. Last, a Compartment represents a container for other components, such as a cell or an intracellular compartment. All species and reactions of the molecular maps are annotated with textual comments and hyperlinks to record the supporting information and its source (see data files S1 and S3).
Generation of logical models
We built our logical models using the software GINsim (www.ginsim. org), relying on the molecular maps previously generated. GINsim implements the multivalued logical modeling formalism introduced by Thomas and D'Ari (80) . This formalism relies on the delineation of a regulatory graph (LRG), where each component (protein or more abstract biological function) is represented by a logical node (taking the values 0 or 1, or additional values when justified) and each influence (activation or inhibition) between a pair of components is represented by a signed arc. Next, a logical rule is assigned to each node in the network, which determines its activation level according to the levels of its regulators. These logical rules involve literals (component values) and the logical operators AND, OR, and NOT (81, 82) . We confirmed the expression of all model components in unstimulated naïve CD4 + T cells using RNA-seq and ChIP-seq data reported by the BLUEPRINT consortium (table S1). A gene was considered expressed if it could be associated with regions with chromatin marks denoting active promoters or enhancers, together with an expression value of at least 1 RPKM (reads per kilobase of transcripts per million mapped). ChIP-seq peaks of histone modifications were given as input to the software ChromHMM (http://compbio.mit. edu/ChromHMM/) (with the parameters BinerizeBed -center option, assembly hg38; LearnModel 10 states) to segment the genome in different regions according to their chromatin states. We then selected the regions associated with marks of active promoters (H3K4me3 
Model analysis
The two original models for the TCR and TLR5 signaling pathways were merged, and the logical rules of shared nodes were updated to take into account the additional regulatory inputs (Fig. 5, table S4 , and data file S5). We computed the stable states of the two original and merged models under wild-type and mutant conditions. We further generated a reduced version of the merged model ( fig. S4 ) to explore its dynamical behavior. All of the analyses were performed with GINsim [as previously described (81) (82) (83) (84) ], which supports model reduction by hiding selected (intermediate) nodes. Provided that no functional regulatory circuit is eliminated in the process, this reduction preserves all attractors (81) . The dynamical behavior of a logical model is represented by a state transition graph (STG). In this graph, each node represents a state of the model, which is defined by a vector encompassing the levels of all components, and the arcs represent transitions between states. One core function of GINsim is the automatic construction of this graph (82) . When the number of components in a model is large, the resulting STG becomes difficult to compute and to visualize. In this respect, GINsim enables the generation of a hierarchical transition graph (HTG), which is computed by clustering the nodes of an STG into groups of states (hyper-nodes) sharing the same set of successors (84) . Last, computing the HTG for different initial conditions enabled us to identify all of the attractors of our merged model for wild-type and mutant scenarios (see Results).
Cell isolation and culture
Leukocyte concentrates were obtained from healthy donors from the Centro Estatal de la Transfusión Sanguínea, Cuernavaca, Mexico. Peripheral blood mononuclear cells were obtained from these cellular concentrates through centrifugation with Ficoll-Hypaque gradient. Total CD4 + T cells were obtained using the RosetteSep CD4 + T cell enrichment cocktail (STEMCELL) and 1 ml of erythrocytes from the same donor. We depleted memory cells with an anti-CD45RO antibody (Tonbo) coupled to magnetic beads (Pierce) with the help of a magnetic rack. Naïve CD4 + T cells obtained this way were cultured in RPMI medium supplemented with 5% fetal bovine serum (FBS) at 37°C with 5% CO 2 . Cell preparations were routinely checked for purity and were at least 96% CD3 + CD4 + , CD45RO − , and 96% CCR7 + CD62L + .
CD4
+ T cell stimulation Naïve CD4 + T cells were either left unstimulated or stimulated by cross-linking the CD3 receptor (simulating TCR ligation), with flagellin (to activate TLR5), with both stimuli (TCR + TLR5 activation), or by cross-linking CD3 and CD28 (TCR + CD28 activation). The activation of the following molecules was evaluated by flow cytometry: p65 (pp65), CREB (pCREB), and c-Jun (pc-Jun). Cells were stimulated in RPMI medium supplemented with 2% FBS. The following antibodies were used at 1 and 0.1 g/ml in different combinations: anti-CD3 (OKT3) antibody (Tonbo), anti-CD28 (CD28.2) antibody (Tonbo), and polyclonal goat anti-mouse antibody (BioLegend) to cross-link the anti-CD3 and anti-CD28 antibodies. TLR5 signals were induced with flagellin monomer (InvivoGen) at final concentrations of 250 or 25 ng/ml.
Flow cytometry
To evaluate the purity of cell preparations, the following markers were evaluated by extracellular staining: CD3, CD4, CD45RO, CD45RA, CCR7, and CD62L. This consisted of the incubation of cells with antibody solutions for 30 min at 4°C, washing with phosphate-buffered saline (PBS) supplemented with 2% FBS, and a fixation step with 1% formaldehyde. The following antibodies were used: anti-CD3-PE (phycoerythrin) (Tonbo), anti-CD4-allophycocyanin (BioLegend), anti-CD62L-PE (Miltenyi Biotec), anti-CCR7-FITC (fluorescein isothiocyanate) (Miltenyi Biotec), anti-CD45RO-FITC (Tonbo), and anti-CD45RA-FITC (Miltenyi Biotec). The activation of p65, CREB, and c-Jun was evaluated by intracellular staining. This consisted of the fixation of cells with 1.5% formaldehyde for 10 min, a permeabilization step with cold absolute methanol for 10 min (0°C) or more (−80°C), a washing step with PBS supplemented with 2% FBS, incubation with antibody solution for 30 min at 4°C, and another washing step together with a final fixation step with 1% formaldehyde. Activations of p65, c-Jun, and CREB were evaluated by flow cytometry. Activation was determined by evaluating the phosphorylated protein in specific reported residues. We used anti-pc-Jun (Ser 63 ) (GeneTex), anti-pCREB (Ser 133 ) (Pierce), a secondary anti-rabbit-FITC (GeneTex), and anti-pp65 (Ser 529 )-allophycocyanin (Miltenyi Biotec) antibodies. A FACSCanto II (BD Biosciences) cytometer was used, and data analysis was performed using the FlowJo software (Tree Star, CA). Changes in the amount of activated proteins across pairs of conditions were assessed using Kruskal-Wallis tests and the software GraphPad Prism 7 (see tables S6 to S8).
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